UPDATE: Stifel Downgrades ChemoCentryx (CCXI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms
May 7, 2021 9:36 AM EDTShares of ChemoCentryx (NASDAQ: CCXI) crashed 55% in pre-open Friday after the Food and Drug Administration (FDA) raised concerns over the approval application of the product avacopan.
We are grateful to the Committee for their careful deliberations and look forward to working with the FDA as its review of our application continues, said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. Discussion from patients and clinicians during the public forum portion of the meeting underscored the need for new treatment options.
The FDA is primarily concerned that the therapy could not... More
Raymond James Downgrades ChemoCentryx (CCXI) to Outperform
May 7, 2021 7:38 AM EDTRaymond James analyst Steven Seedhouse downgraded ChemoCentryx (NASDAQ: CCXI) from Strong Buy to Outperform with a price target of $51.00 (from $120.00).
The analyst commented, "To be clear, our downgrade to Outperform from Strong Buy is based on reduced conviction in avacopan being approved by July 7 PDUFA given Thursdays AdCom discussion and vote. However, if approved we still think avacopan is a... More
ChemoCentryx (CCXI) sinks 45% as trading resumes following mixed FDA AdCom
May 7, 2021 7:15 AM EDTChemoCentryx (NASDAQ: CCXI) sinks 45% as trading resumes following mixed FDA AdCom.
... MoreChemoCentryx (CCXI) Reports Mixed FDA AdCom Vote For Avacopan
May 7, 2021 6:48 AM EDTChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the FDA Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting, the Committee voted on three questions presented by the FDA:
The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with... More
UPDATE: JPMorgan Downgrades ChemoCentryx (CCXI) to Underweight
May 7, 2021 4:01 AM EDT(Updated - May 7, 2021 5:12 AM EDT)
JPMorgan analyst Anupam Rama downgraded ChemoCentryx (NASDAQ: CCXI) from Neutral to Underweight with a price target of $17.00 (from $57.00).
The analyst comments "We hold an Underweight rating on CCXI shares. ChemoCentryx is a biotechnology company with a focus on developing oral drugs that target the chemokine system, which is... More
Piper Sandler Downgrades ChemoCentryx (CCXI) to Neutral
May 6, 2021 7:04 PM EDTPiper Sandler analyst Edward Tenthoff downgraded ChemoCentryx (NASDAQ: CCXI) from Overweight to Neutral with a price target of $25.00.
For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.
Shares of ChemoCentryx closed at $27.49 yesterday.
... MoreChemoCentryx (CCXI) Halted, News Pending
May 6, 2021 6:55 AM EDTChemoCentryx (NASDAQ: CCXI) Halted, News Pending
... More